Artificial womb technology (AWT) crosses into human application with the Children’s Hospital of Philadelphia (CHOP) launching Phase 1 trials of the EXTEND system in late 2025, targeting extreme preterm infants (22-24 weeks) to slash mortality and morbidity by 50%. This fluid-filled biobag, mimicking amniotic environments, sustains fetoneatal development via umbilical cannulation and gas exchange, building on lamb studies where lambs gained 28 days’ gestation with lung maturity rivaling in-utero peers.
FDA’s breakthrough designation fast-tracks EXTEND, emphasizing ethical safeguards: informed consent, equitable access, and oversight for coercion risks in vulnerable families. Preclinical RNA sequencing affirms physiological fidelity, with organ profiles mirroring late-preterm norms versus ventilator-induced inflammation. Japan’s University of Tokyo completes animal validations, integrating AI monitoring for real-time fetal vitals, while EU’s FLUniversal consortium eyes congenital malformation therapies.
Ethical debates intensify: partial ectogenesis as “innovative treatment” versus research demands rigorous IRB protocols, addressing bonding disruptions and inequality. Yet, for 15 million annual preterms facing 1 million deaths and lifelong disabilities, AWT promises paradigm-shifting care—reducing NICU stays by weeks, cutting costs by billions, and redefining viability’s boundary.
